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Background: Between 40,000 and 80,000 pregnant women die annually from pre-eclampsia and eclampsia. Although
magnesium sulphate and anti-hypertensive therapies can reduce the morbidity and mortality associated with
pre-eclampsia, the only cure comes with delivery. Prompt delivery of the baby, preferably by vaginal route, is vital in
order to achieve good maternal and neonatal outcomes. Induction of labour is therefore a critical intervention in order
to prevent morbidity to both mother and baby. Two low cost interventions – oral misoprostol tablets and transcervical
Foley catheterization – are already used by some in low resource settings, but their relative risks and benefits are not
known. The trial will compare the risks, benefits, and trade-offs in efficacy, safety, acceptability and cost of misoprostol
and Foley catheter for induction in women with preeclampsia or uncontrolled hypertension.
Methods/Design: A total of 602 women with an ongoing pregnancy with a live fetus requiring delivery because of
pre-eclampsia or uncontrolled hypertension will be randomly assigned to labor induction with a transcervical Foley
catheter or oral misoprostol 25 micrograms. Women will be recruited at two hospitals in Nagpur, India. The misoprostol
group will receive oral misoprostol 25 microgram every 2 hours for a maximum of 12 doses or until active labor
commences. The Foley group will undergo induction using a Foley catheter (silicone, size 18 F with 30 ml balloon)
which will remain until active labor starts, the Foley catheter falls out, or 12 hours have elapsed. The primary outcome
will be the attainment of vaginal delivery within 24 hours. Providers administering the treatment and those assessing
the outcomes will not be blinded to group assignment.
Trial registration: NCT01801410 (ClinicalTrials.gov).
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Between 40,000 and 80,000 pregnant women die annually
from pre-eclampsia and eclampsia [1]. Magnesium sulphate
and anti-hypertensive therapies can reduce the morbidity
and mortality associated with pre-eclampsia [2,3]. The only
cure, however, comes with delivery. Prompt delivery of the
baby, preferably by vaginal route, is vital in order to achieve
good maternal and neonatal outcomes. Induction of labour
is therefore a critical intervention in order to prevent mor-
bidity and mortality to both mother and baby. Two low* Correspondence: hbracken@gynuity.org
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cal Foley catheterization – are already used by some in low
resource settings, but their relative risks and benefits are
not known. These interventions could optimize the care
pathway for women needing induction of labour. This is es-
pecially important in low resource settings where improve-
ment is most needed and the potential to reduce the
maternal and neonatal mortality and morbidity is the great-
est. The ideal induction agent would result in a relatively
short induction to delivery interval without risk to fetus
and with low rates of emergency caesarean section. The
induction to delivery interval is especially important in
pre-eclampsia and eclampsia where the condition may de-
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glandin E1 analogue, has been used for labour induction
for nearly 20 years. Following years of debate about appro-
priate dosage, it appears that the use of oral misoprostol
25 microgram is optimal [4,5]. A systematic review of low
dose oral misoprostol included two trials in which the 25
microgram dose of oral and vaginal misoprostol were
compared. It found that “women using oral misoprostol
were significantly less likely to experience uterine hyper-
stimulation with fetal heart rate changes (2% compared
with 13%; RR 0.19, 95% CI 0.08-0.46), but there were no sig-
nificant differences in other outcomes [6]”. The Cochrane
review concluded that “Given that safety is the primary
concern, the oral regimens are recommended over vaginal
regimens. This is especially important in situations where
the risk of ascending infection is high and the lack of staff
means that women cannot be intensely monitored [4]”.
Oral misoprostol is very effective but still has a hyperstim-
ulation rate of 6% [6], potentially causing hypoxic damage
to the fetus. The risk of hypoxic damage is increased in
pre-eclampsia, where babies may be born prematurely
or affected by intrauterine growth restriction. In low re-
source settings, where access to intrapartum fetal moni-
toring may be limited, avoidance of hyperstimulation,
which may go undetected, is critical.
Alternative low cost methods have been sought that
can induce labour with potentially less risk to the fetus.
Such an agent may be the Foley catheter. Although usu-
ally used for bladder drainage, these catheters can be
inserted into the cervix and held there by inflating the
balloon. The catheter is then placed on gentle traction
by strapping it to the mother’s thigh and left for 12 hours
or until it falls out through the cervical os. Induction
with the Foley balloon catheter appears to be as effective
as current standard methods, but with lower rates of
uterine hyperstimulation and better fetal outcomes [7,8].
However, the majority of the studies (22/30) were con-
ducted in Western settings. Little is known about the
rates and risks of infection in low resource settings.
Low-dose misoprostol appears to be an effective alterna-
tive for labor induction although inductions with prosta-
glandins, including misoprostol, are sometimes associated
with uterine hyperstimulation and consequent fetal hyp-
oxia. The Foley balloon induction method may have con-
siderable safety benefits for the fetus, although there is
conflicting evidence as to its effect on the speed of induc-
tion. Both methods are promising, but the relative risks
and benefits of the two methods for labor induction
among women with pre-eclampsia in low resource set-
tings has yet to be established in a large, randomized trial.
We will conduct a multicentre randomized trial compar-
ing misoprostol treatment with Foley balloon induction
for labor induction in women with preeclampsia or un-
controlled hypertension. This study will identify the risk,benefits and trade-offs in efficacy, safety, acceptability and
cost of these two low cost induction methods.
Methods
This pragmatic, open-label, randomised control trial will en-
roll patients seeking care for preeclampsia at Government
Medical College and Daga Women’s Hospital, Nagpur.
Women with an ongoing pregnancy with a live fetus
in whom the decision has been made to induce vaginal
delivery because of preeclampsia or uncontrolled hyper-
tension will be included. Women will be excluded if they
are less than 18 years old; have previously undergone a
caesarean section; present with a multiple pregnancy, rup-
tured membranes, or chorioamnionitis; or report a history
of allergy to misoprostol. All subjects will provide written
and oral informed consent and have the informed consent
process video recorded as required by Indian regulations.
This protocol was approved by the Liverpool School of
Tropical Medicine Research Ethics Committee (Approval
number 12.26) and the Ethics Committee at Government
Medical College, Nagpur and will be conducted in compli-
ance with the Helsinki Declaration.
Randomisation
At enrolment, the medical history will be assessed and a
physical exam will be performed (Figure 1). Women will
be randomised independently using a computerised ran-
dom number generator; the randomisation will be stratified
by centre using a randomly determined block size. The
group assignment will be indicated in a card sealed in se-
quentially numbered opaque envelopes. The group assign-
ment will be revealed immediately prior to the start of the
induction. The participants, providers, and those assessing
outcomes will not be blinded to the group assignment.
Women in the mechanical group will undergo induction
using a transcervical Foley catheter (silicone, size 18 F
with 30 ml balloon) which will remain in place until active
labour starts, the Foley catheter falls out, or 12 hours have
elapsed. If the Foley catheter falls out within 12 hours,
membranes will be ruptured and/or oxytocin infusion
started. If the Foley catheter does not fall out within
12 hours, it will be removed at 12 hours and oxytocin
commenced with an artificial rupture of membranes when
possible. If labour has still not commenced after 24 hours,
the woman will be deemed to have a ’failed induction’ and
the decision on further management will be made by the
clinical team. Their choice of method could include the
use of misoprostol, repeat Foley catheter, dinoprostone,
caesarean section or delay as deemed appropriate.
Women in the misoprostol group will be induced using
oral misoprostol tablets (25 micrograms, Cipla Ltd, Mumbai)
every 2 hours for a maximum of 12 doses or until active
labour commences. In primigravid women, if contractions
have not commenced after 2 doses, the dosage may be
Figure 1 Consort flow diagram.
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(regular painful contractions with a cervical dilatation of
at least 4 cm) no more misoprostol will be used and artifi-
cial membrane rupture and/or oxytocin infusion will be
used as clinically indicated. If labour has still not com-
menced after 24 hours, the woman will be deemed to have
a ‘failed induction’ and the decision on further manage-
ment will be made by the clinical team. Their choice of
method could include the use of misoprostol, repeat Foley
catheter, dinoprostone, caesarean section or delay as
deemed appropriate.
During the labor induction, women will be monitored by
research clinicians every two hours. The use of any add-
itional medications, cervical dilation and Bishop score will
be recorded, as appropriate.
Women will be asked to assess their expectations prior
to the induction process. Then, within 48 hours of deliv-
ery and prior to discharge, women will be interviewed
by study staff using a short questionnaire. The question-
naire will assess their opinions about their experience
and issues surrounding the induction (including time to
induction), their satisfaction with the actual labour, and
their perspectives on the two medical technologies.
Women will be asked to rate their overall experience on
a categorical five-point scale from ‘very unsatisfied’ to‘very satisfied’ and compare this to their actual experience,
with a focus on what they would like to change in any fu-
ture induction. Care providers’ (nurses and doctors) opin-
ions will also be collected in a separate provider survey (or
focus group discussion where appropriate) after the con-
clusion of the trial.
Participants with severe pre-eclampsia will receive magne-
sium sulfate and anti-hypertensives as per local protocols.
Study outcomes
The primary outcome will be the attainment of vaginal de-
livery within 24 hours. Vaginal delivery within 24 hours is
the standard primary outcome suggested in the Cochrane
Collaboration induction of labour generic protocol [5,6]. It
combines an acceptable time period for the induction
process as well as the combined fetal and maternal safety
outcome of need for caesarean section. Caesarean section
also poses a serious risk to maternal health in the context
of the setting and disease.
Secondary outcomes will assess the success of the in-
duction process, neonatal morbidity and mortality, and
maternal mortality and morbidity. Measures of efficacy
of the induction process will include the induction to
delivery interval (in vaginal deliveries, caesarean sections
and all deliveries), the proportion of women in each
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vix unchanged at 12 and 24 hours, and with a need for
oxytocin augmentation. Measures of maternal complica-
tions will include uterine tachysystole (defined as over 5
contractions in 10 minutes), uterine hypertonus (defined as
a single contraction lasting over 2 minutes), caesarean sec-
tion, uterine rupture, instrumental vaginal delivery, severe
hypertension and HELLP Syndrome, maternal vomiting,
maternal diarrhoea, fever, antibiotic use, and postpartum
haemorrhage. Data on the following fetal-neonatal com-
plications will also be collected: meconium-stained liquor,
Apgar score less than seven at five minutes, neonatal in-
tensive care unit admission, seizures, birth asphyxia, and
stillbirth.
Statistical analysis
The primary outcome will be vaginal birth within 24 hours.
The rate of vaginal delivery within 24 hours in the Foley
catheter group is estimated at 41%. This rate is taken from
the study by Pennell [9] which compared a Foley catheter
for 12 hours with vaginal misoprostol and found a rate of
vaginal delivery in the Foley group within 24 hours of 53/
110 (48%) [9]. Only two other studies were identified that
used the same induction protocol and outcomes as planned
for this study (i.e. a 12 hour Foley under traction and an
outcome of vaginal birth within 24 hours). In Yuen [10] the
vaginal delivery rate within 24 hours was 15/36 (42%), and
in Owolabi [11] the rate was 17/60 (28%) [10,11]. The com-
bined rate from these 3 studies is 85/206 (41%).
In the Cochrane review of oral misoprostol 25 microgram
versus PGE2 which included 5 trials, the vaginal delivery
rate within 24 hours in the 25 microgram oral misoprostol
group was 654/1089 (60%) [4]. The vaginal delivery rate in
this study is likely to be increased because there will be little
intrapartum fetal monitoring, a factor that is known to in-
crease caesarean section rates. However, more women will
be having labor induced preterm (with more unfavourable
Bishop scores) – a factor that also increases caesarean sec-
tion rates. Our estimated rate of vaginal delivery within
24 hours in the misoprostol group is therefore 60%.
The null hypothesis is that there is no difference in the
rate of vaginal delivery within 24 hours in those induced
with misoprostol and those induced with a Foley cath-
eter. This hypothesis will be rejected if there is a 33%
difference in the outcomes with the two methods. To
detect an absolute increase from 41% to 55% with 90%
power (two-sided α = 0.05) will require a sample of 602
women. If the vaginal birth rate in the Foley group is
higher, then the study will have more power. As stated
previously, we do not anticipate any loss to follow-up.
Proposed analyses
Logistic, Poisson and negative binomial regression models
will be used as appropriate to estimate effect size (differencein vaginal delivery rates) with 95% confidence intervals; ad-
justments will be made for important confounding variables
and covariates. The primary analysis will be done according
to intention to treat. If indicated, a secondary, per protocol
analysis will be performed. Similar regression models will
be used to compare the two study groups with respect to
other important (secondary) variables. Subgroup analyses
will be parity (nulliparous or not), site of delivery, Bishop
score (≥6 or less), and perceived fetal viability (determined
by the provider at enrolment).
We will conduct an economic evaluation to assess pat-
terns and levels of resource utilisation associated with
the two induction techniques. This analysis will enable
any variations in resource use between the two treat-
ment groups to be identified, measured and valued and
facilitate the linking of patterns/costs of resource use to
maternal and child health outcomes and other agreed
measures of ‘effectiveness’ and ‘success’.
An interim analysis will be conducted after one year of
recruitment, or when data are available from the first
300 women. The data will be reviewed by an independ-
ent Data Monitoring Committee. Further interim ana-
lyses are not planned, but may be requested by the Data
Monitoring Committee. No interim analyses for effect-
iveness or futility are planned.
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